Search

Durability of transcatheter heart valve (THV) is critical as the indication of transcatheter aortic valve implantation (TAVI) expands to patients with longer life-expectancy. We aimed to compare the durability of different THV systems (balloon-expandable [BE] and self-expandable [SE]) and surgical aortic valve replacement (SAVR) prosthesis. PUBMED and EMBASE were searched through February 2021 for randomized trials investigating parameters of valve durability after TAVI and/or SAVR in severe aortic stenosis. A network meta-analysis using random-effect model was performed. Synthesis was performed with 5-year follow-up data for echocardiographic outcomes and the longest available follow-up data for clinical outcomes. Ten trials with a total of 9,388 patients (BE-THV: 2,562; SE-THV: 2,863; SAVR: 3,963) were included. Follow-up ranged from 1 to 6 years. SE-THV demonstrated significantly larger effective orifice area, lower mean aortic valve gradient (AVG), and less increase in mean AVG at 5-year compared with BE-THV and SAVR. Structural valve deterioration (SVD) was less frequent in SE-THV compared with BE-THV and SAVR (HR 0.14, 95% CI 0.07 to 0.27; HR 0.34, 95% CI 0.24 to 0.47, respectively). Total moderate-severe aortic regurgitation and reintervention was more frequent in BE-THV (HR 4.21, 95% CI 2.40 to 7.39; HR 2.22, 95% CI 1.16 to 4.26, respectively), and SE-THV (HR 7.51, 95% CI 3.89 to 14.5; HR 2.86, 95% CI 1.59 to 5.13, respectively) compared with SAVR. In conclusion, TAVI with SE-THV demonstrated favorable forward-flow hemodynamics and lowest risk of SVD compared with BE-THV and SAVR at mid-term. However, both THV systems suffer an increased risk of AR and re-intervention, and long-term data from newer generation valves is warranted., Competing Interests: Disclosures The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Dr. Azeem Latib reports the following disclosures: consultant (honoraria) ‐ Edwards Lifesciences, Abbott Vascular; Boston Scientific, Medtronic, Philips, WL Gore; Scientific Advisory Boards (equity) ‐ Tioga, Supira, NeoChord, CorFlow, ICS, VVital, and Institutional Funding to Montefiore Medical Center from ‐ Edwards Lifesciences, Medtronic, Abbott Vascular, Boston Scientific. Dr. Lars Søndergaard has received consultant fees and institutional research grants from Abbott, Boston Scientific and Medtronic. Dr. Guilherme Attizzani has received research grants, functions as a consultant and is on the advisory board of Medtronic. Dr. Duane Pinto reports the following disclosures: consultant (honoraria)- Abbott Vascular, Abiomed, Boston Scientific, Magenta, Medtronic, NuPulseCV, Inari, Terumo, Teleflex. Institutional Funding to Beth Israel Deaconess Medical Center from- Abiomed, Medtronic, Boston Scientific, Abbott Vascular. The other authors report no conflicts., (Copyright © 2021 Elsevier Inc. All rights reserved.)

Hemorrhagic stroke (HS) is a feared complication of Fibrinolytic therapy (FT). Risk assessment scores may help in risk stratification to reduce this complication. Patients (admissions) ≥18 years with a primary diagnosis of ST-elevation myocardial infarction (STEMI) who received systemic thrombolysis were extracted from Nationwide Inpatient Sample database and stratified and compared based on CHA 2 DS 2 VASC score 0 to 3, 4 to 6, and 7 to 9 as low, intermediate and high risk, respectively. The primary outcomes of interest were HS and mortality. We performed logistic regression analysis with a composite of HS and mortality as the primary end point. Of the 917,307 admissions with a primary diagnosis of STEMI, 39,579 (4.3%) underwent FT. The median score was 3 (interquartile range 1 to 5). The rate of HS significantly increased in the risk category compared with the low and intermediate groups (0.5% and 0.6% vs 4.1%; p <0.001). Mortality increased with increasing risk category (3.8% vs 10.5% vs 20.7%; p <0.001). Compared with the low-risk group patients in the intermediate (odds ratio 2.11 95% confidence interval [CI] 1.56 to 2.85; p <0.001) and high risk groups (odds ratio 3.47 95% CI 1.68 to 7.2; p <0.001) were more likely to experience the composite end point of HS or inpatient mortality. CHA 2 DS 2 VASC score performed better at predicting mortality (area under curve 0.67, 95% CI 0.64 to 0.7; p = 0.014) than HS (area under curve 0.6 95% CI 0.52 to 0.69; p = 0.021). In conclusion, patients with high CHA 2 DS 2 VASC score (7 to 9) are at a higher risk of hemorrhagic stroke and death after FT for STEMI. CHA 2 DS 2 VASC score performed better at predicting mortality than hemorrhagic stroke in this cohort., (Copyright © 2018. Published by Elsevier Inc.)

Characteristics of conduction disorders after ST-elevation myocardial infarction (STEMI) have been well described. In contrast, limited data are available on the incidence, treatment trends, and prognostic impact of conduction disorders after non-ST-elevation myocardial infarction (NSTEMI). Using the National Inpatient Sample database, we compared the characteristics and outcomes of conduction disorders in patients with a primary diagnosis of STEMI versus NSTEMI between 2010 and 2014. Conduction disorders were classified into‬ high-degree AV block (HDAVB), consisting of complete AV block or Mobitz type II second-degree AV block, and sinoatrial node dysfunction (SND). We identified 135,468 STEMI patients and 281,928 NSTEMI patients. In contrast to the STEMI cohort where HDAVB was more common than SND (2.4% vs 0.5%), SND was observed more often in the NSTEMI cohort, presenting in 2,417 patients (0.9%), followed by HDAVB in 1,745 patients (0.6%). In patients who developed HDAVB, NSTEMI patients were more likely to undergo permanent pacemaker implantation than STEMI patients (30.0% vs 11.6%; p < 0.001). The rate of permanent pacemaker implantation for SND was comparable between STEMI and NSTEMI patients (33.9% vs 30.5%; p = 0.10). In the NSTEMI cohort, patients who developed HDAVB had higher in-hospital mortality than those without any major conduction disorders (16.6% vs 3.8%; p < 0.001). In conclusion, SND was more common than HDAVB in the NSTEMI cohort, in contrast to the predominance of HDAVB observed in the STEMI cohort. About one-third of patients who developed HDAVB after NSTEMI underwent pacemaker implantation, suggesting lower rates of spontaneous resolution of HDAVB, when compared with STEMI patients., (Copyright © 2018. Published by Elsevier Inc.)

Anatomical SYNTAX score (SS1) and SYNTAX score II (SS2) are often utilized to determine the optimal revascularization strategy. Although US veterans have unique characteristics that may affect outcomes after revascularization, the prognostic values of SS1 and SS2 in veterans have not yet been validated. We performed a retrospective analysis of consecutive veteran patients who underwent percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) for left main and/or 3-vessel disease from 2009 to 2014. SS1 and SS2 were calculated for each patient. The primary outcome was all-cause mortality. The prognostic values of SS1 and SS2 were compared by receiver operating characteristic curve analysis. The predicted 4-year mortality derived from SS2 was compared with the observed 4-year mortality estimated from Kaplan-Meier analysis. After exclusion, 286 patients (99% male) were included. Among 286 patients, 79 patients (27.6%) had left main disease, 151 (52.8%) underwent PCI, and 135 (47.2%) underwent CABG. Overall mortality was 27.6% at a median follow-up of 5.0 years. SS2 had better discriminative ability for all-cause mortality than SS1 (c-index 0.79 vs 0.52, p <0.001). Observed and predicted 4-year mortality correlated well in patients with low and intermediate SS2 in both PCI and CABG cohorts, but observed mortality was higher than predicted in the PCI cohort with high SS2 (observed 54.7% vs predicted 40.5%). In conclusion, observed and predicted 4-year mortality derived from SS2 correlated well in patients with low and intermediate SS2, but SS2 underestimated mortality in the PCI cohort with high SS2., (Copyright © 2018 Elsevier Inc. All rights reserved.)

Sickle-cell disease (SCD) affects millions worldwide. Sickle-cell anemia (SCA), the most severe form of this disease, is the most common inherited blood disorder in the United States. There are limited data on the incidence, clinical characteristics, and outcomes of acute myocardial infarction (AMI) in these patients. Using data from the National Inpatient Sample database, we matched cases (AMI with SCA) with controls (AMI without SCA) in a 1:1 ratio for age, gender, race, and year of admission. We compared both groups in terms of clinical characteristics and inpatient outcomes and performed a logistic regression with mortality as the primary outcome. Using weighted samples, we also described trends of SCA in the general population of patients with AMI. Of the 2,386,657 admissions with AMI, SCA was reported in 501 (0.02%) patients, and 495 were successfully matched to controls. Patients with SCA were less likely to have risk factors for coronary artery disease than those without SCA. Patients with SCA were more likely to develop pneumonia, respiratory failure, and acute renal failure, and require mechanical ventilation, hemodialysis for acute renal failure and blood transfusion. In-hospital mortality was significantly higher in patients with SCA. In a multivariate analysis, SCA was an independent predictor of mortality (odds ratio 3.49; 95% confidence interval 1.99 to 6.12; p = < .001). In conclusion, myocardial infarction occurs in patients with SCA at a relatively early age. These patients do not typically have the traditional risk factors for the acute coronary syndrome. Mortality in these patients is significantly higher in age-, gender-, and race-matched controls., (Copyright © 2017 Elsevier Inc. All rights reserved.)